For research use only. Not for therapeutic Use.
Imrecoxib (Cat.No:I007290), also known as BAP-909, a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Imrecoxib was found to inhibit COX-1 and COX-2 with IC50 value of 115+/-28 nmol/L and 18+/-4 nmol/L, respectively. Imrecoxib was shown to selectively and dose-dependently inhibit COX-2 mRNA level. Imrecoxib effectively inhibited carrageenan-induced acute inflammation at the doses of 5, 10, and 20 mg/kg i.g. and adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg/d i.g.
| Catalog Number | I007290 |
| CAS Number | 395683-14-4 |
| Synonyms | BAP-909; BAP 909; BAP909; Imrecoxib;4-(4-(Methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1H-pyrrol-2(5H)-one |
| Molecular Formula | C21H23NO3S |
| Purity | ≥95% |
| Target | COX 2 inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | 4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2H-pyrrol-5-one |
| InChI | InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3 |
| InChIKey | AXMZZGKKZDJGAZ-UHFFFAOYSA-N |
| SMILES | CCCN1CC(=C(C1=O)C2=CC=C(C=C2)C)C3=CC=C(C=C3)S(=O)(=O)C |
| Reference | </br>1:[Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice]. Wang DC, Wang LC, Wang LJ, Chen G, Zhao YX, Zhao ZF, Li YH.Zhonghua Zhong Liu Za Zhi. 2016 May 23;38(5):340-5. doi: 10.3760/cma.j.issn.0253-3766.2016.05.004. Chinese. PMID: 27188605 </br>2:Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Feng Z, Chu F, Guo Z, Sun P.Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. doi: 10.1016/j.bmcl.2009.02.090. Epub 2009 Feb 27. PMID: 19286379 </br>3:Metabolism and excretion of imrecoxib in rat. Xu H, Zhang Y, Sun Y, Zhang P, Chu F, Guo Z, Zhang H, Zhong D.Xenobiotica. 2006 May;36(5):441-55. PMID: 16854781 </br>4:Formation of 4/’-carboxyl acid metabolite of imrecoxib by rat liver microsomes. Xu HY, Zhang P, Gong AS, Sun YM, Chu FM, Guo ZR, Zhong DF.Acta Pharmacol Sin. 2006 Apr;27(4):506-12. PMID: 16539853 Free Article</br>5:Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib. Xu HY, Xie ZY, Zhang P, Sun J, Chu FM, Guo ZR, Zhong DF.Acta Pharmacol Sin. 2006 Mar;27(3):372-80. PMID: 16490176 Free Article</br>6:[Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs]. Li Q, Huang HH, Dong Y, Zhong DF.Yao Xue Xue Bao. 2005 Oct;40(10):912-5. Chinese. PMID: 16408808 </br>7:Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF.Acta Pharmacol Sin. 2004 Jul;25(7):927-31. PMID: 15210067 Free Article |
